We navigate our future based on
the founding philosophy and
business direction of
GCMS.
GCMS is one of the first-generation service providers of vitro diagnosis, which we used import in the 1960s and 70s. Our company dates back to 1972 when GCMS jumped into the in vitro diagnosis business by setting up a dedicated organization and has achieved phenomenal growth. GC Pharma spun off its Diagnosis Business Division to set up an independent corporation dedicated to diagnostic reagent in 2004. GC Pharma has made remarkable contributions in leading the growth and development of our domestic diagnosis industry for the past four decades.
Since 1972 when the first blood grouping reagent was introduced to market, our company has developed and distributed a variety of sophisticated reagents to medical institutions at home and abroad. These include infectious diseases (HIV, HBV, HCV etc.) test reagents, and tumor marker and parasitological test reagents which require very advanced technologies.
In addition, the company established a cooperative marketing partnership in 1978 with Boehringer Ingelheim, a world class diagnostic reagent company based in Germany, and co-founded Green Cross Boehringer Ingelheim Co., Ltd., a cooperative joint venture in 1992. This joint venture enabled the company to achieve impressive growth in the major areas of in vitro diagnosis, including clinical immunity, clinical chemistry, and diabetes diagnosis. The company also developed and introduced GENEDIA HIV 1/2 ELISA, an HIV/AIDS diagnostic reagent, for the first time in Korea in 1987 through long-term consistent R&D efforts as part of our commitment to promoting public health.
GCMS was founded in 2004 as an independent corporation in a bid to diversity our business portfolio to medication equipment, and devices and other supplies in addition to the in vitro diagnosis business.
GCMS has achieved annual growth of 20% or more in its relevant market, and more recently pushed ahead with upgrading diagnostic reagents based on real-time molecular reagents and specific recombination antibody forming technology.
As such, GC Pharma has made consistent efforts to develop and introduce market-oriented products under the motto “Open R&D/Innovation” while seeking to solidify its image as a ‘global player’ as we boost our effort to develop products targeting international markets around the world, including the US, Russia, Europe, Africa, Middle East, and India.
Our mission is
'Devotion to healthy lives of people',
and our vision is to become
'A global leader in the healthcare industry'.
GCMS has consistently walked its path to develop specialty pharmaceuticals that are difficult to build but are indispensable for healthy lives of people for the past half century.
It has been a lonely path disregarded by others. However, GCMS has devoted its efforts to developing novel drugs in a steadfast manner because of our sincere aspiration, and a sense of mission towards promoting healthy life for all human beings.
We find it worthwhile to help all people live free from disease and physical agony and focus instead on fulfilling their dreams, enjoying life, and pursuing their happiness under a calm and stable mental state.
GCMS is committed to becoming a global leader in various sectors of the healthcare industry, including pharmaceuticals, medical equipment, and healthcare services, particularly through prevention, diagnosis and treatment of disease so that people are able to maintain physical as well as mental health.
Established in Hong Kong to facilitate an IPO in China, GCHK is the parent company of GC China and plays a pivotal role in financing its subsidiary.
GC China, established as part of GC Pharma’ global expansion strategy, produces plasma-derived products. Since passing the Chinese National Health and Family Planning Commission of the People’s Republic of China’s on-site inspection and obtaining a safety certificate in 1998, the company has gone on to become the first in Anhui Province to satisfy the Chinese government’s Good Manufacturing Practice (GMP) standard with its advanced systems and facilities. The company currently procures the blood plasma it needs from seven depositories in total, including six in Anhui and one in Hunan.
A subsidiary of GC China, GC Chinapharm is a pharmaceutical wholesaler established by GC Pharmaj for the distribution of pharmaceutical products in China. The company is expected to buttress GC China’s continued growth through effective marketing and distribution of GC China products to local clients. Gelinker currently operates six distributorships across the nation, including the main one at Shanghai.
The holding company of GCBT, GCNA provides efficient financing for GCBT.
Established in Montreal as a forward base for launching into the plasma-derived product market in North America, GCBT is currently building its plant. The products it will produce will mainly target the advanced North American markets in the United States and Canada after the authorities’ approval.
Boasting quarantine and containment systems of the highest quality, Invacfarm produces and supplies fertile eggs from its state-of-the-art poultry farm and hatcheries, which meet the standard for vaccine production. Invacfarm provides a steady supply of quality eggs to GC Pharma, performing an indispensable role in the company’s development and production of flu vaccines.
(16907) 15, Youggu-daero 2469beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do (Bojeong-dong)
TEL +82-31-260-0965 FAX +82-31-260-9416 E-MAIL gcms.overseas@greencross.com
COPYRIGHT(C) GC MEDICAL SCIENCE CORP. ALL RIGHTS RESERVED.